



**CANONSBURG
GENERAL HOSPITAL**

WEST PENN ALLEGHENY HEALTH SYSTEM

100 MEDICAL BOULEVARD, CANONSBURG, PA 15317

724-745-6100

FAX: 724-873-5876

November 16, 2005

NM581

U.S. Regulatory Commission
Materials Licensing Branch
Region I
475 Allendale Road
King of Prussia, PA 19406

03013169

37-17688-01

RE: Amendment to Radioactive Materials License No. ~~37-17699-01~~
Canonsburg General Hospital *mal*

RECEIVED
NOV 17 2005
12:58

Gentlemen:

Please add authorization for use of materials in 10 CFR 35.400 for use in manual brachytherapy.

Please add Russel Fuhrer, M.D., David Parda, M.D., Stephen Michael Karlovitis, M.D., Athanasios Colonias, M.D., Steven Lee Anolik, M.D., Youssef Arshoun, M.D., Vinod Shaw, M.D., and Mark Trombetta, M.D., as authorized users under 10 CFR 35.400.

Training and experience for the above referenced physicians can be found on license number 37-18104-01 (Forbes Regional Hospital) or through authorization by Allegheny General Hospital (Broadscope license). Specific authorization are included with this amendment.

If you have any questions or require additional clarification, please do not hesitate to contact the undersigned.

Sincerely,


Kim Malinky, CEO

138004

NMOS/RGNI MATERIALS-002

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grant Russell Fuhrer, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212 or 3290 William Pitt Way, Building 9, Pittsburgh, PA 15238. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Russell Fuhrer, M.D.
Authorized User
2. 58
Permit Number
3. Radiation Oncology
Department or Section
4. August 22, 2000
Approval Date
5. Human Use Isotope Group 35.400 and depleted U-235 shielding
Authorized Use
6. Group III Group II Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{avg} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. H. Isaacs
Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

8/22/00
Date

Joseph G. Och
Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

8/22/00
Date

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Stephen Michael Karlovitis, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Stephen Michael Karlovitis, M.D.
Authorized User
2. 60
Permit Number
3. Radiation Oncology
Department or Section
4. July 10, 2001
Approval Date
5. Human Use Isotope Group 35,400 and depleted U-235 shielding
Authorized Use

6. Group III Group II Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{avg} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. H. Isaacs
Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

July 19, 2001
Date

Joseph G. Och
Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

July 19, 2001
Date

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Athanasios Colonias, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Athanasios Colonias, M.D.
Authorized User
2. 59
Permit Number
3. Radiation Oncology
Department or Section
4. July 10, 2001
Approval Date
5. Human Use Isotope Group 35.400 and depleted U-235 shielding
Authorized Use
6. Group III Group II Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{avg} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. H. Isaacs
Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

July 19, 2001
Date

Joseph G. Och, M.S.
Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

July 19, 2001
Date

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Steven Lee Anolik, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Steven Lee Anolik, M.D.
Authorized User

2. 52
Permit Number

3. Radiation Oncology
Department or Section

4. July 10, 2001
Approval Date

5. Human Use Isotope Group 35.400 and depleted U-235 shielding
Authorized Use

6. Group III Group II Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{avg} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. H. Isaacs
Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

July 19, 2001
Date

J. G. Och
Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

July 19, 2001
Date

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Vinod Shah, M.D. Authorized User status under NRC license 37-01317-01 and PA license PA-0031 and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Vinod Shah, M.D.
Authorized User

2. 63
Permit Number

3. Radiation Oncology
Department or Section

4. February 11, 2003
Approval Date

5. Human Use Isotope Group

35.100 35.200 35.300 X 35.400 35.500 X 35.600
X 35.1000 (Endovascular) depleted U-235 shielding

6. Authorized Use

Group I Group II Group III

Group I isotopes (high radiotoxicity): beta ≥ 300 keV E_{avg} ; gamma ≥ 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

7. Restrictions: NONE

Approval Signatures:

John Rehder
John Rehder, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

2-11-03
Date

Joseph G. Och
Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

2/11/03
Date

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Youssef Arshoun, M.D. Authorized User status under NRC license 37-01317-01 and PA license PA-0031 and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Youssef Arshoun, M.D.
Authorized User

2. 64
Permit Number

3. Radiation Oncology
Department or Section

4. March 11, 2003
Approval Date

5. Human Use Isotope Group

35.100 35.200 35.300 X 35.400 35.500 X 35.600
X 35.1000 (ENDOVASCULAR THERAPY) depleted U-235 shielding

6. Authorized Use

Group I Group II Group III

Group I isotopes (high radiotoxicity): beta ≥ 300 keV E_{avg} ; gamma ≥ 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

7. Restrictions: NONE

Approval Signatures:

John Rehder
John Rehder, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

3/24/03
Date

Joseph G. Och
Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

3/24/03
Date

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Mark Trombetta, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212 or 3290 William Pitt Way, Building 9, Pittsburgh, PA 15238. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Mark Trombetta, M.D.
Authorized User
2. 57
Permit Number
3. Radiation Oncology
Department or Section
4. August 22, 2000
Approval Date
5. Human Use Isotope Group 35.400 and depleted U-235 shielding
Authorized Use
6. Group III Group II Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{avg} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. H. Isaacs
Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

8/22/00
Date

Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

8/22/00
Date

412-774-2225

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES
Amendment No. 21

Duplicate

MATERIALS LICENSE

Duplicate

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Forbes Regional Hospital

2. 2570 Haymaker Road

Monroeville, Pennsylvania 15146-3592

In accordance with the application dated
May 27, 20043. License number 37-18104-01 is amended in
its entirety to read as follows:

4. Expiration date July 31, 2014

5. Docket No. 030-14474

Reference No.

6. Byproduct, source, and/or special
nuclear materialA. Any byproduct material
permitted by 10 CFR 35.1003. Any byproduct material
permitted by 10 CFR 35.2005. Any byproduct material
permitted by 10 CFR 35.3001. Any byproduct material
permitted by 10 CFR 35.400Any byproduct material
permitted by 10 CFR 31.11

Chemical and/or physical form

A. Any

Any

C. Any

D. Sealed Sources

(North American Scientific Inc.

Model MED 3631, Mills

Biopharmaceuticals Inc.,

Models 125SL and 125SH,

Medi-Physics Inc. Model 6711,

International Brachytherapy,

SA Model 1251L, Draximage

Model LS-1, Best Medical

International Model 2301,

Bard Brachytherapy, Inc.

Model STM1251)

E. Prepackaged Kits

8. Maximum amount that licensee may
possess at any one time under this
license

A. As needed

B. As needed

C. 500 millicuries

D. 1 curie

E. 5 millicuries

Duplicate

Duplicate

Duplicate

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

Duplicate

MATERIALS LICENSE
SUPPLEMENTARY SHEET

Duplicate

License Number

67-18104-01

Duplicate

Docket or Reference Number

030-14474

Amendment No. 21

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In vitro studies.

10. Licensed material may be used or stored only at the licensee's facilities located at 2570 Haymaker Road, Monroeville, Pennsylvania

11. The Radiation Safety Officer for this license is Stephen R. DeLong, M.D.

12. Licensed material is only authorized for use by or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses indicated:

Authorized UsersMaterial and Use

Stephen R. DeLong, M.D.

35.100; 35.200; 35.300

In vitro studies

Frank G. Diettinger, M.D.

35.100; 35.200

In vitro studies

Ave M. Bacher, M.D.

35.100; 35.200

In vitro studies

Eric W. Flint, M.D.

35.100; 35.200; oral administration of sodium iodide-iodine-131 for imaging and localization studies

In vitro studies

David F. Lackner, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for imaging and localization studies

In vitro studies

Duplicate

Gerald J. Ross, M.D.

Duplicate

35.100; 35.200; 35.300

In vitro studies

Duplicate

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

Duplicate
MATERIALS LICENSE
SUPPLEMENTARY SHEET

Duplicate

License Number

37-18104-01

Docket or Reference Number

030-14474

Amendment No. 21

Carol L. Seifert, M.D.

35.100; 35.200; oral administration of sodium
 iodide iodine-131 for imaging and localization
 studies
In vitro studies

Vera R. Sperling, M.D.

35.100; 35.200; oral administration of sodium
 iodide iodine-131 for imaging and localization
 studies
In vitro studies

Frank Perrone, M.D.

35.100; 35.200
In vitro studies

Leonard A. DeFogli, M.D.

35.100; 35.200; 35.300

William Scott Morse, M.D.

35.100; 35.200

Denise Marie Chough, M.D.

35.100; 35.200

James W. Thomas, M.D.

35.100; 35.200; oral administration of sodium iodide
 iodine-131 for imaging and localization studies
In vitro studies

Steven Lee Anolik, M.D.

35.400

Russell Fuhrer, M.D.

35.400

Steven Michael Karlovitis, M.D.

35.400

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

Duplicate

Duplicate

Duplicate

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES

Duplicate

MATERIALS LICENSE
SUPPLEMENTARY SHEET

Duplicate

License Number

97-18104-01

Duplicate

Docket or Reference Number


030-14474

Amendment No. 21

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 27, 2004

B. Letter dated June 24, 2004



For the U.S. Nuclear Regulatory Commission

ate July 26, 2004

By

Original signed by James P. Dwyer

James P. Dwyer

Nuclear Materials Safety Branch 1

Division of Nuclear Materials Safety

Region 1

King of Prussia, Pennsylvania 19406

Duplicate

Duplicate

Duplicate

This is to acknowledge the receipt of your letter/application dated

11/16/2005, and to inform you that the initial processing which includes an administrative review has been performed.

☒ ATTEND. 37-17688-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 138004.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.